{
    "xml": "<topic id=\"PHP493\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/mesalazine\" basename=\"mesalazine\" title=\"MESALAZINE\">\n<title>MESALAZINE</title>\n<body>\n<data name=\"vtmid\">86977007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_819175722\" title=\"Aminosalicylates\">Aminosalicylates</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34554\" title=\"AMINOSALICYLATES\" namespace=\"/drug-classes/aminosalicylates\">AMINOSALICYLATES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP41436\" outputclass=\"indicationsAndDose\" rev=\"1.11\" parent=\"/drugs/mesalazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41449\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/mesalazine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elderly</ph>; <ph outputclass=\"caution\">pulmonary disease</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41435\" outputclass=\"interactions\" rev=\"1.18\" parent=\"/drugs/mesalazine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>The manufacturers of some mesalazine gastro-resistant and modified-release medicines (<i>Asacol</i>\n<tm tmtype=\"reg\"/> MR tablets, <i>Ipocol</i>\n<tm tmtype=\"reg\"/>, <i>Salofalk</i>\n<tm tmtype=\"reg\"/> granules) suggest that preparations that lower stool pH (e.g. lactulose) may prevent the release of mesalazine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41428\" outputclass=\"sideEffects\" rev=\"1.9\" parent=\"/drugs/mesalazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dizziness</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Oligospermia (reversible)</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41433\" outputclass=\"pregnancy\" parent=\"/drugs/mesalazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Negligible quantities cross placenta.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41453\" outputclass=\"breastFeeding\" parent=\"/drugs/mesalazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Diarrhoea reported in breast-fed infants, but negligible amounts of mesalazine detected in breast milk.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInBreastFeeding\">\n<sectiondiv>\n<p>Monitor breast-fed infant for diarrhoea.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41437\" outputclass=\"hepaticImpairment\" parent=\"/drugs/mesalazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41431\" outputclass=\"renalImpairment\" parent=\"/drugs/mesalazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use with caution.</p>\n<p>Avoid if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59463\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.16\" parent=\"/drugs/mesalazine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Flavours of granule formulations of <i>Salofalk</i>\n<tm tmtype=\"reg\"/> may include vanilla.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP41432\" outputclass=\"patientAndCarerAdvice\" rev=\"1.31\" parent=\"/drugs/mesalazine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.</p>\n<p>Some products may require special administration advice; patients and carers should be informed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP493-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/mesalazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76341\" title=\"Modified-release tablet\" namespace=\"/drugs/mesalazine/modified-release-tablet\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76265\" title=\"Gastro-resistant tablet\" namespace=\"/drugs/mesalazine/gastro-resistant-tablet\">Gastro-resistant tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76421\" title=\"Modified-release granules\" namespace=\"/drugs/mesalazine/modified-release-granules\">Modified-release granules</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77348\" title=\"Foam\" namespace=\"/drugs/mesalazine/foam\">Foam</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77270\" title=\"Suppository\" namespace=\"/drugs/mesalazine/suppository\">Suppository</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77425\" title=\"Enema\" namespace=\"/drugs/mesalazine/enema\">Enema</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"3\" rel=\"backlink\">Inflammatory bowel disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34554\" namespace=\"/drug-classes/aminosalicylates\" title=\"AMINOSALICYLATES\" count=\"1\" rel=\"link\">AMINOSALICYLATES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76341\" namespace=\"/drugs/mesalazine/modified-release-tablet\" title=\"Modified-release tablet\" count=\"1\" rel=\"link\">Modified-release tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76265\" namespace=\"/drugs/mesalazine/gastro-resistant-tablet\" title=\"Gastro-resistant tablet\" count=\"1\" rel=\"link\">Gastro-resistant tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76421\" namespace=\"/drugs/mesalazine/modified-release-granules\" title=\"Modified-release granules\" count=\"1\" rel=\"link\">Modified-release granules</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77348\" namespace=\"/drugs/mesalazine/foam\" title=\"Foam\" count=\"1\" rel=\"link\">Foam</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77270\" namespace=\"/drugs/mesalazine/suppository\" title=\"Suppository\" count=\"1\" rel=\"link\">Suppository</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77425\" namespace=\"/drugs/mesalazine/enema\" title=\"Enema\" count=\"1\" rel=\"link\">Enema</xref>\n</links>\n</topic>",
    "id": "PHP493",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/mesalazine",
    "basename": "mesalazine",
    "title": "MESALAZINE",
    "vtmid": "86977007",
    "drugClassification": [
        "Aminosalicylates"
    ],
    "inheritsFromClass": [
        "AMINOSALICYLATES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.",
                "html": "<p>There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elderly",
                "html": "Elderly"
            },
            {
                "type": "cautions",
                "textContent": "pulmonary disease",
                "html": "pulmonary disease"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "The manufacturers of some mesalazine gastro-resistant and modified-release medicines (Asacol MR tablets, Ipocol , Salofalk granules) suggest that preparations that lower stool pH (e.g. lactulose) may prevent the release of mesalazine.",
                "html": "<p>The manufacturers of some mesalazine gastro-resistant and modified-release medicines (<i>Asacol</i>\n<tm tmtype=\"reg\"/> MR tablets, <i>Ipocol</i>\n<tm tmtype=\"reg\"/>, <i>Salofalk</i>\n<tm tmtype=\"reg\"/> granules) suggest that preparations that lower stool pH (e.g. lactulose) may prevent the release of mesalazine.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Dizziness",
                        "html": "Dizziness",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Oligospermia (reversible)",
                        "html": "Oligospermia (reversible)",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Negligible quantities cross placenta.",
                "html": "<p>Negligible quantities cross placenta.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Diarrhoea reported in breast-fed infants, but negligible amounts of mesalazine detected in breast milk.",
                "html": "<p>Diarrhoea reported in breast-fed infants, but negligible amounts of mesalazine detected in breast milk.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor breast-fed infant for diarrhoea.",
                "html": "<p>Monitor breast-fed infant for diarrhoea.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use with caution.\n\nAvoid if eGFR less than 20 mL/minute/1.73 m2.",
                "html": "<p>Use with caution.</p><p>Avoid if eGFR less than 20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Flavours of granule formulations of Salofalk may include vanilla.",
                "html": "<p>Flavours of granule formulations of <i>Salofalk</i>\n<tm tmtype=\"reg\"/> may include vanilla.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.\n\nSome products may require special administration advice; patients and carers should be informed.",
                "html": "<p>If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.</p><p>Some products may require special administration advice; patients and carers should be informed.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76341",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76265",
                "label": "Gastro-resistant tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76421",
                "label": "Modified-release granules",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77348",
                "label": "Foam",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77270",
                "label": "Suppository",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77425",
                "label": "Enema",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "drugClass": [
            {
                "id": "PHP34554",
                "label": "AMINOSALICYLATES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76341",
                "label": "Modified-release tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76265",
                "label": "Gastro-resistant tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76421",
                "label": "Modified-release granules",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77348",
                "label": "Foam",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77270",
                "label": "Suppository",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77425",
                "label": "Enema",
                "type": "medicinalForm"
            }
        ]
    }
}